MONTREAL, QUEBEC--(Marketwire - November 09, 2007) - Adaltis Inc. (TSX: ADS), an international in vitro diagnostic (IVD) company, today reported its third quarter 2007 financial results. Financial Highlights: - Revenue for the three months ended September 30, 2007 was $14.6 million compared to $12.0 million in 2006, an increase of $2.6 million, or 21.7%. This increase is driven by $1.5 million of increased sales in our higher margin products, including our infectious disease product lines buoyed by increased sales in China and other emerging countries such as Russia, Brazil, and India. It was also due to $1.4 million of growth in sales of lower margin products in Asia, and was partially offset by the unfavorable impact of foreign exchange fluctuations of $0.3 million.
